Prelude Therapeutics Inc. is a clinical-stage oncology firm headquartered in Wilmington, Delaware, dedicated to the development of precision small molecule therapies targeting pivotal cancer drivers. The company boasts a promising pipeline, underpinned by its proprietary drug discovery platform, which aims to deliver innovative treatment solutions for patients with advanced malignancies. With an emphasis on precision medicine, Prelude is strategically positioned to make significant contributions to the evolving cancer therapeutics landscape, appealing to institutional investors seeking exposure to transformative biotech innovations.